Postmenopausal bleeding: investigation pathway, endometrial-cancer risk and the RCOG GTG 67 hyperplasia interaction

A 63-year-old woman tells you she has had "a brownish smear" for two days, a year after her last period. The temptation is to reassure her that "at this age it's just atrophy". Do not. That smear carries the same endometrial-cancer risk as a heavy bleed — about 9% — and PMB is the symptom that captures roughly 90% of endometrial cancers. Your job is to run a structured one-stop workup, exclude cancer, and treat the cause. This topic is the investigation pathway.^[1][4]

Overview and definition

PMB is an umbrella term for any vaginal bleeding, however small, that happens 12 months or more after the last menstrual period. The 12-month anchor matters: a woman who is still menstruating is perimenopausal, not postmenopausal, and her bleeding is worked up as reproductive-age abnormal uterine bleeding (cross-link to the AUB topic). Once she has passed 12 months of amenorrhoea, any bleeding is PMB and is cancer until proven otherwise.^[1][12]

The definition deliberately casts a wide net, because the signal-to-noise trade-off favours over-investigation:^[1]

• Most PMB is benign — atrophy is the commonest cause — but the minority that is cancer is early and curable if found.
• Volume does not predict malignancy. A spot, a smear, a single episode and a heavy bleed carry the same cancer risk.
• PMB is the gateway symptom. About 91% (95% CI 87-93%) of women with endometrial cancer report it.^[1]

^{[1] [2]}

References12ShowHide

1. [1]Clarke MA, Long BJ, Del Mar Morillo A, et al. Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis. JAMA Intern Med, 2018.PMID 30083701
2. [2]Karlsson B, Granberg S, Wikland M, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding--a Nordic multicenter study. Am J Obstet Gynecol, 1995.PMID 7755059
3. [3]Smith-Bindman R, Kerlikowske K, Feldstein VA, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA, 1998.PMID 9809732
4. [4]Vroom FR, Prins MM, Bongers MY, et al. Endometrial SamPling befoRe or aftEr Saline infusion SOnography (ESPRESSO Trial): a national survey and a study protocol of a multicenter RCT. Minerva Ginecol, 2017.PMID 28252269
5. [5]Vroom FR, Timmermans A, Bongers MY, et al. Diagnostic accuracy of saline contrast sonohysterography in detecting endometrial polyps in women with postmenopausal bleeding: systematic review and meta-analysis. Ultrasound Obstet Gynecol, 2019.PMID 30693579
6. [6]Dijkhuizen FP, Mol BW, Brölmann HA, et al. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer, 2000.PMID 11042572
7. [7]van Hanegem N, Breijer MC, Opmeer BC, et al. Prediction models in women with postmenopausal bleeding: a systematic review. Womens Health (Lond), 2012.PMID 22554173
8. [8]Parkash V, Fadare O, Tornos C, et al. ACOG Committee Opinion No. 631: Endometrial Intraepithelial Neoplasia. Obstet Gynecol, 2015.PMID 26393443
9. [9]Wolfman W, Leyland N, Heywood M, Singh SS, et al. Asymptomatic endometrial thickening. J Obstet Gynaecol Can, 2010.PMID 21176311
10. [10]Henderson E, Black G, Khattak A, et al. Diagnosis and management of endometrial hyperplasia: A UK national audit of adherence to national guidance 2012-2020. PLoS Med, 2024.PMID 38421942
11. [11]Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia. Cancer, 2006.PMID 16400639
12. [12]Abdelraheim AR, Khairy M, Mohammed M, Lawrence A Two week waits: What are we waiting for? Eur J Obstet Gynecol Reprod Biol, 2017.PMID 28609712